drugset / Trial / NCT05727176
Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
RandomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, multinational, randomized Phase 2 study confirming the clinical benefit of 20 mg futibatinib and evaluating the safety and efficacy of 16 mg futibatinib in previously treated CCA harboring FGFR2 gene fusions and other rearrangements.
Timeline
- Start
- 2023-07-05
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Futibatinib | Small molecule | 16 mg | Oral |
| Subject | Futibatinib | Small molecule | 20 mg | Oral |